COVID-19 & CancerFree Doroshow: NCI to accrue patients for COVID-19 longitudinal cohortOngoing trials see significant decrease in accrual April 17, 2020Vol.46 No.16By Matthew Bin Han Ong
COVID-19 & CancerFree Lowy: “Our patients are counting on us, and we must not let them down”NCI Frederick lab takes aim at Covid-19 April 17, 2020Vol.46 No.16By Matthew Bin Han Ong
COVID-19 & CancerFreeNCI Sharpless: NCI is fully operational, we have a moral obligation to help in the COVID-19 pandemic response April 14, 2020Vol.46 No.16By Matthew Bin Han Ong
Conversation with The Cancer LetterCOVID-19 & CancerFree A view from the plateau: As Italy’s cases drop, oncologists plan post-COVID-19 agenda April 10, 2020Vol.46 No.15By Alexandria Carolan
COVID-19 & CancerFree NCI to distribute IL-6 inhibitor for cancer patients with COVID-19 lung inflammation April 10, 2020Vol.46 No.15By Matthew Bin Han Ong
COVID-19 & CancerFreeGuest Editorial Chernobyl doctor’s view of COVID-19: Trump threatens 267 years of progress in biomedical research April 10, 2020Vol.46 No.15By Robert Peter Gale
COVID-19 & CancerFreeGuest Editorial NCTN group chairs: Cancer trials take backseat to clinical care amid COVID-19 pandemic April 10, 2020Vol.46 No.15By Charles D. Blanke, Douglas S. Hawkins, Monica M. Bertagnolli, Peter J. O'Dwyer, Mitchell D. Schnall, Walter J. Curran, Norman Wolmark, Robert S. Mannel and Janet Dancey
Conversation with The Cancer LetterCOVID-19 & CancerFree COVID-19 lesson from Spain: Like the U.S., we failed to take this seriously before it came to us—we have to learn April 09, 2020Vol.46 No.15By Matthew Bin Han Ong
Conversation with The Cancer LetterCOVID-19 & CancerFree Libutti: Rutgers studies COVID-19 while bracing for its surge April 06, 2020Vol.46 No.15By Paul Goldberg
COVID-19 & CancerFreeTrials & Tribulations COVID-19 and cancer: Ethical dilemmas in immune checkpoint blockade April 03, 2020Vol.46 No.14By Allison Betof Warner
